James Brumley

The suggestion seems outrageous until you look at all the businesses it's in and begin crunching some numbers.

Any combination is possible. There's one particular one, however, that just makes good logistical and geographic sense.

While everyone else is fighting to own a stock that's likely to be down significantly in the foreseeable future, I'll be stepping into this overlooked, discounted opportunity.

It's become too much of a risk to simply ignore now. If there was any lingering hope that April's inflation surge was a one-off event, it was just wiped away.

The artificial intelligence start-up's board of directors is showing some serious confidence in the company's future.

The market may be hyperfocused on growth right now, but there are some overlooked dividend-paying treasures just waiting to be discovered.

You're familiar with the company's premise and the stock's past and projected valuation. Now it's time to look at it and the IPO through a more philosophical lens.

Medical science's capabilities are catching up with what it knows about the genomics of disease. J&J just made sure it's better equipped to utilize the industry's newest capabilities.

Everyone's feeling more pain at the gas pump and grocery store, but some older Americans will get some help pretty soon.

The recent surge in inflation has forced institutions and individuals to make some strategic, defensive hedging trades they wouldn't normally make.